OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

August 28th 2017

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Diehn on Next Steps With Liquid Biopsies in Lung Cancer

August 25th 2017

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

Dr. Gandara on the MYSTIC Trial for Lung Cancer

August 25th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

August 25th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

August 25th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Dr. Roboz on Evolving Paradigms in AML Treatment

August 25th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).

Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

August 25th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Dr. Nanus Discusses Early Stage Kidney Cancer Treatment

August 25th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.

Dr. Grob on the Tolerability and Efficacy of Ipilimumab in Melanoma

August 24th 2017

Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.

Dr. Campbell on the Future of the Management of RCC

August 24th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

August 24th 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Dr. Leonard on Precision Medicine in Hematologic Malignancies

August 24th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the advance of precision medicine across hematologic malignancies.

Dr. Siegel on Benefits With Transoral Surgery and Chemotherapy for Head and Neck Cancer

August 24th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the benefits of chemotherapy and transoral surgery for patients with head and neck cancer.

Dr. Hammers on Next Steps with Immunotherapy in RCC

August 24th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer

August 23rd 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.

Dr. Feldman Discusses Metabolomic Findings in Prostate Cancer

August 23rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Dr. Trotman on BGB-3111 in Patients With Waldenstrom's Macroglobulinemia

August 23rd 2017

Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.

Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML

August 23rd 2017

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

Dr. Lallas Discusses Multidisciplinary Care for Genitourinary Malignancies

August 23rd 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses multidisciplinary care for genitourinary malignancies.